Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 27, 2012. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,300,000 Ordinary Shares of 25 pence each.
- Purchase Date: September 27, 2012.
- Price Range: Highest price paid was 1,449.5 pence per share; lowest price paid was 1,434 pence per share.
- Treasury Holdings (Settled): 498,115,427 shares (9.15% of total issued share capital).
- Treasury Holdings (Including Unsettled): 501,165,427 shares (10.13% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,946,068,939 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,300,000 shares. This transaction increased the proportion of shares held in Treasury from the prior level to 9.15% of issued capital (or 10.13% of voting rights when including unsettled shares). No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (498,115,427 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.15% treasury holding percentage.
- Check the settlement status of the 3,050,000 shares included in the "unsettled" count to determine the final voting rights impact.
- Review the remaining authorization for share buybacks under the May 3, 2012 shareholder mandate.